{"filings":[{"id":584317,"accession_number":"0001628280-26-037387","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-05-21T21:18:49+00:00","items":["5.02"],"status":"ready","headline":"Zai Lab President & COO Josh Smiley departs; responsibilities absorbed by CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Josh Smiley ceases as President and COO effective May 18, 2026; last day is May 22, 2026.","CEO Samantha Du and management team assume his responsibilities.","Smiley receives severance under his existing employment agreement subject to release.","No replacement named; Du retains roles as Board Chair, Founder and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94836,"accession_number":"0001628280-26-031624","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.","Net loss $51M ($0.46/ADS); operating loss $69.4M; cash $761.3M at March 31.","Zoci (DLL3 ADC) delivered 62.5% confirmed intracranial ORR in SCLC brain mets at AACR; 38.2% ORR in epNECs.","Clinical collaborations with Amgen and Boehringer Ingelheim to evaluate zoci combinations in SCLC and NECs.","Appointed Yizhe Wang, Ph.D., as Operating Partner; KarXT launch preparations underway; TIVDAK under regulatory review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":99611000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107497,"accession_number":"0001704292-26-000014","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).","Net loss Q4 $50.4M (loss per ADS $0.46) vs $81.7M loss Q4 2024; FY loss $175.5M vs $257.1M.","Cash $789.6M as of Dec 31, 2025; R&D expenses $61.6M Q4 (+18% YoY).","KarXT approved in China Dec 2025; commercial launch H1 2026; NRDL renewals for VYVGART, NUZYRA, ZEJULA.","Global pipeline: zoci (DLL3 ADC) advancing to three registration-enabling studies; ZL-1503 Phase 1 data H2 2026; ZL-1311 IND by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":460156000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123850,"accession_number":"0001704292-25-000023","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.","Operating loss improved 28% YoY to $48.8M GAAP; adjusted operating loss $28.0M (-42% YoY).","Net loss $36.0M ($0.33/ADS) vs $41.7M ($0.42/ADS) in Q3 2024.","Global registrational study for zoci (DLL3 ADC) initiated; Phase 1 data showed 68% ORR at 1.6 mg/kg in 2L+ ES-SCLC.","Cash $817.2M; FY2025 revenue guidance revised to at least $460M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":332559000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123849,"accession_number":"0001704292-25-000014","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB300M ($42.1M) revolving credit facility from Industrial Bank for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Guarantee and credit line contract with Industrial Bank for up to RMB300M (~$42.1M) to Zai Lab Shanghai.","Facility available until May 5, 2026; each loan expected one-year term.","No loans drawn to date; facility for working capital in mainland China.","Contains customary covenants including prior consent for certain transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140515,"accession_number":"0001628280-25-038547","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).","GAAP operating loss $54.9M (improved 28% YoY); adjusted operating loss $34.2M (improved 37% YoY).","Net loss $40.7M vs $80.3M YoY; cash $832.3M as of June 30, 2025.","Reaffirms FY2025 revenue guidance $560M-$590M; on track for adjusted profitability in Q4 2025.","Pipeline: ZL-1310 ORR 79% at 1.6mg/kg in 2L ES-SCLC; bemarituzumab Phase 3 met OS endpoint; China submission H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":216464000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.77,"calibrated_materiality_score":0.77,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158218,"accession_number":"0001628280-25-032099","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zai Lab shareholders approve all 14 proposals at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All director nominees re-elected, including Samantha Du, John Diekman, Richard Gaynor, Nisa Leung, William Lis, Scott Morrison, Leon Moulder, Michel Vounatsos, and Peter Wirth.","Ratification of KPMG as independent auditor for FY2025 approved (794,030,890 for).","Advisory say-on-pay for named executive officers passed with 636,374,843 votes for.","General mandates to allot/issue up to 10% of shares and to repurchase up to 10% of shares both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158217,"accession_number":"0001628280-25-023410","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.","Adjusted operating loss $37.1M, improved 25% YoY; net loss $48.4M vs $53.5M prior year.","Cash $857.3M; reaffirms FY2025 revenue guidance $560M-$590M.","ZL-1310 (DLL3 ADC) pivotal study in ES-SCLC expected H2 2025; ASCO data June 2.","Discontinued ZL-1102 (IL-17) Phase 2 trial after interim analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":106487000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176580,"accession_number":"0001628280-25-008406","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.","VYVGART franchise net revenue $93.6M in first full year; ZEJULA $187.1M (+11% YoY); NUZYRA $43.2M (+99% YoY).","Loss from operations decreased 23% to $282.1M for FY2024; net loss per ADS $2.60 vs $3.46 in 2023.","Cash position $879.7M as of Dec 31, 2024; expects adjusted profitability (non-GAAP) in Q4 2025.","ZL-1310 (DLL3 ADC) SCLC trial showed 74% ORR; NDA accepted for KarXT in schizophrenia in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":398988000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176579,"accession_number":"0001628280-25-000261","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB300M ($41.1M) revolving credit facility from Bank of Communications","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Guarantee and loan contract signed Jan 2, 2025 with BOCOM for working capital loans to subsidiary Zai Lab Shanghai.","Facility available until Sep 26, 2025; each loan term up to 12 months, maturity no later than Mar 26, 2026.","Interest rate set at one-year LPR minus 35 bps, adjusted quarterly.","Covenants include BOCOM consent for M&A, equity transfers, or debt financing exceeding RMB1.5B (~$205.5M).","No working capital loans drawn under the facility as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193432,"accession_number":"0001193125-24-259957","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Zai Lab prices $200M ADS offering at $25.50 per ADS; net proceeds ~$189M for general corporate purposes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 7,843,137 ADSs at $25.50 per ADS; expected gross proceeds ~$200M.","Net proceeds after underwriting discounts and expenses expected ~$189M; closing on or about Nov 18, 2024.","Underwriters granted 30-day option to purchase up to 1,176,470 additional ADSs at offering price.","Proceeds to be used for general corporate purposes; offering made under effective shelf registration S-3ASR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193431,"accession_number":"0001628280-24-047588","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.","Two Chinese patents covering Optune were successfully invalidated; decision on appeal. Optune-related patents expected to expire within two years.","Company warns of material adverse effects from data privacy non-compliance, anti-corruption investigations (including FCPA), and licensing disputes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193430,"accession_number":"0001628280-24-046809","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).","VYVGART sales $27.3M (vs $4.9M YoY); ZEJULA $48.2M (+16%); NUZYRA $10.0M (+82%).","KarXT bridging study in schizophrenia met primary endpoint (9.2-point PANSS reduction, p=0.0014); NDA submission expected early 2025.","ZL-1310 (DLL3 ADC) Phase 1 data shows 74% ORR in extensive-stage SCLC; potential best-in-class.","Cash position $716.1M; three product launches in China expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":289918000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209751,"accession_number":"0001628280-24-035194","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.","Net loss $80.3M ($0.82/ADS loss), improved from $120.9M loss ($1.25/ADS) in Q2 2023.","Raises full-year VYVGART revenue guidance to exceed $80.0M; cash position $730.0M as of June 30.","Three NMPA product approvals: XACDURO (HABP/VABP), efgartigimod SC (gMG), AUGTYRO (ROS1+ NSCLC).","Expanded global oncology pipeline with next-gen ROR1 ADC (ZL-6301) via MabCare partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":187653000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209750,"accession_number":"0001628280-24-031485","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB250M credit facility from China Merchants Bank for subsidiary working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Parent company issued guarantee to China Merchants Bank (Shanghai) for loans up to RMB250M (~$34.4M) for wholly owned subsidiary Zai Lab Shanghai.","Credit facility is for one year; specific loan terms will be in separate transaction documents.","No working capital loans have been drawn under the facility as of the filing date.","Facility supports working capital needs in mainland China; includes customary covenants requiring prior bank consent for certain transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227926,"accession_number":"0001628280-24-028764","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Zai Lab shareholders approve 2024 equity plan, re-elect all directors at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Equity Incentive Plan approved (568.4M for, 215.2M against), replacing 2022 Plan with more shares.","All 10 director nominees re-elected, including Samantha Du and Leon Moulder Jr.","Advisory vote on named executive officer compensation passed (530.4M for, 253.2M against).","General mandate to issue up to 20% of shares (for allotment) and repurchase mandate up to 10% approved.","KPMG ratified as auditor for FY2024 (783.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227925,"accession_number":"0001628280-24-027668","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zai Lab CMO Dr. Harald Reinhart to retire; Dr. Rafael Amado to lead all Global R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Harald Reinhart, President, Head of Global Development (NSAiID), retiring effective June 30, 2024.","Reinhart will remain as a senior advisor; no disagreements led to his retirement.","Dr. Rafael Amado expands role to President, Head of Global R&D upon Reinhart's retirement.","Amado previously President of Global Oncology R&D; now oversees all therapy areas.","CEO Samantha Du noted Reinhart built strong NSAiID team for continued growth under Amado."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}